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Fungal diseases are increasing among patients infected with human immunodeficiency
virus (HIV) type 1. Infections due to Candida and Cryptococcus are the most common.
Although mucocutaneous candidiasis can be treated with oral antifungal agents, increasing
evidence suggests that prolonged use of these drugs results in both clinical and microbi-
ologic resistance. The optimal therapy for cryptococcal meningitis remains unresolved,
although initial treatment with amphotericin B, followed by life-long maintenance therapy
with fluconazole, appears promising. Most cases of histoplasmosis, coccidioidomycosis,
and blastomycosis occur in regions where their causative organisms are endemic, and
increasing data suggest that a significant proportion of disease is due to recent infection.
AspergillosisisincreasingdramaticallyasanopportunisticinfectioninHIV-infectedpatients,
in part because of the increased incidence of neutropenia and corticosteroid use in these
patients. Infection due to Penicillium marneffei is a rapidly growing problem among HIV-in-
fected patients living in Southeast Asia. Although the advent of oral azole antifungal drugs
has made primary prophylaxis against fungal diseases in HIV-infected patients feasible,
many questions remain to be answered before the preventive use of antifungal drugs can be
advocated.
Over the last decade, the incidence of fungal
infections has increased dramatically. The human
immunodeficiency virus (HIV) type 1 epidemic
accounts for a large share of this increase. This
article is not a general guide to the diagnosis or
treatment of fungal diseases but rather a review
of emerging disease issues in regard to these
infectionsamongHIV-infectedpatients.Theinfec-
tions discussed include candidiasis; cryptococ-
cosis; the endemic mycoses histoplasmosis,
coccidioidomycosis, and blastomycosis; aspergil-
losis; and penicilliosis. In addition, the role of
preventivetherapyforfungalinfectionsinHIV-in-
fected patients is assessed. Fungal pathogens and
their most common manifestations in HIV-in-
fected patients are listed separately (Table).
Candidiasis
Mucocutaneous candidiasis is one of the most
common manifestations of HIV infection. In one
prospective study, 84% of HIV-infected patients
had oropharyngeal colonization by Candida spe-
cies on at least one occasion, and 55% developed
clinical thrush (1). While other yeasts may
occasionally cause clinical disease, Candida albi-
cans is the organism isolated from most patients
(1, 2). Candida species normally colonize the gas-
trointestinal tract of healthy adults, and most
infections in HIV-infected patients are endo-
genouslyacquired.Insomecases,candidalstrains
can be transmitted from person to person (1).
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Table. Common fungal pathogens in HIV infection and their
most frequent clinical syndromes
Organism Clinical syndrome
Candida albicans Thrush, vaginal candidiasis,
esophageal candidiasis
Cryptococcus neoformans Meningitis
Histoplasma capsulatum Disseminated infection with
fever and weight loss
Coccidioides immitis Diffuse and focal pulmonary
disease
Blastomyces dermatitidis Localized pulmonary disease
and disseminated infection,
including meningitis
Aspergillus fumigatus Pulmonary disease with
fever, cough, and hemoptysis
Penicillium marneffei Fever alone or with
pulmonary infiltrates,
lymphadenopathy, or
cutaneous lesions
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pear to be colonized with one or a few dominant
strains, which tend not to change over time. Pow-
derly and colleagues isolated the same strain ofC.
albicans in 11 of 17 patients with recurrent yeast
infection, by DNA probe analysis (2). In another
study, using contour-clamped homogeneous elec-
tric field electrophoresis, Sangeorzan et al. found
that60%ofpatientswerecolonizedwithonedomi-
nant strain of C. albicans. In 74% of these pa-
tients, recolonization with the same strain
occurred after antifungal therapy (1). Using bio-
typing and restriction fragment length polymor-
phism analysis of 25S ribosomal DNA, Whelan
and colleagues found that strains of C. albicans
isolated from 24 patients with AIDS were not
significantly different from strains from 23 pa-
tients without HIV infection (3). Thus, the candi-
dal strains causing disease in patients with HIV
infectionappeartobethesameasthosecolonizing
patients without HIV infection and, in most pa-
tients, do not change over time.
In HIV-infected patients, candidiasis is virtu-
ally always mucocutaneous, involving the oro-
pharynx, the esophagus, and the vagina. HIV
infection by itself is not associated with the syn-
drome of disseminated candidiasis, which is char-
acterized by candidemia, endophthalmitis, and
multiple organ involvement. The precise immu-
nologicprocessesthatcontrolcandidalinfectionin
HIV-infected patients are not known. However,
mucocutaneous candidiasis is clearly related to
the development of clinical cellular immunodefi-
ciency. In fact, oropharyngeal candidiasis is an
independent predictor of immunodeficiency in pa-
tients with AIDS (4). Moreover, aCD4lymphocyte
count < 200/µl is a major risk factor for the devel-
opment of clinical thrush in HIV-infected persons
(1).
Although oropharyngeal candidiasis is fre-
quent in men, recurrent vaginal candidiasis is a
common early manifestation of HIV infection in
women.Thelocationandseverityofcandidiasisin
women with HIV infection appear to be closely
associated with the degree of cellular immunode-
ficiency, based on the peripheral blood CD4 lym-
phocyte count. In a study of 66 women,
mucocutaneous candidiasis developed in more
thanhalfofthewomenoveramedianof14months
offollow-up;vaginalcandidiasis,withameanCD4
lymphocyte count of 506/µl, developed only in 10,
while oropharyngeal candidiasis, with a mean
count of 230/µl developed in 16, and esophagitis,
with a mean count of 30/µl developed in nine (5).
Mucocutaneous candidiasis can be treated
eithertopicallyorwithsystemicantifungalagents
(1, 6), but such therapy does not eradicate coloni-
zation(1).Recently,severalreportshavenotedthe
failure of azole drugs, particularly fluconazole, to
treatrecurrentcasesoforopharyngealcandidiasis
(1, 7). While factors such as diminishing cellular
immunity, drug interactions, or decreased drug
absorption may account for some of these treat-
ment failures, increasing evidence suggests that
Candida organisms are developing drug resis-
tance.
In the past, a lack of consensus on the methods
for performing antifungal susceptibility tests
made it difficult to establish whether clinical fail-
ure of antifungal therapy was due to resistance of
the organism. However, the National Committee
for Clinical Laboratory Standards (NCCLS) has
now developed reference methods allowing for
uniform testing of yeast isolates (8). Using an
NCCLS method, Sangeorzan et al. found that the
MIC of fluconazole forCandida isolates increased
over time among patients who had received flu-
conazole compared with those who received clotri-
mazole. Clinical resistance to fluconazole was
associated with an increased MIC required by the
isolateaswellasthepatient’slowCD4lymphocyte
count (1).These datastronglysuggest thatcontin-
ued use of antifungal agents, particularly flucona-
zole, leads to both clinical treatment failure and
antifungal resistance, especially in highly immu-
nodeficient patients.
Cryptococcosis
Arare disease before the HIV epidemic, crypto-
coccosis was identified very early in the epidemic
as one of the most common life-threatening infec-
tionsinAIDSpatients(9).However,issuesregard-
ing its epidemiology and therapy remain
unresolved.
As i n g l es p e c i e s ,Cryptococcus neoformans,i s
responsible for virtually all clinical cases of cryp-
tococcosis. The species exists in two varieties,neo-
formans and gattii, which inhabit different
ecologic niches. C. neoformans var. neoformans
has been isolated in many parts of the world from
numeroussites,mostfrequentlyfromsoilcontain-
ing high amounts of dried bird excreta, particu-
larly of pigeons and chickens. It has long been
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with such excreta is the most likely source of
cryptococcal infection. However, few data support
this hypothesis. In contrast, the only known
environmental source of C. neoformans var. gattii
is the river red gum tree (Eucalyptus camaldulen-
sis), which grows in rural Australia. Although
infection due to var. neoformans is worldwide,
cases due to var. gattii have only been identified
in tropical and subtropical regions, including ar-
eas where E. camaldulensis is not found (10).
Virtually all instances of cryptococcosis among
HIV-infected persons have been caused by var.
neoformans. The ubiquity of var. neoformans in
the environment may be making exposure and
subsequent infection likely; however, no clear link
has ever been established between environmental
sources of C. neoformans and the development of
cryptococcosis in patients with HIV infection (10).
In a recent study, Varma and colleagues, using
genomicprobeanalysis,couldnotfindadirectlink
between environmental sources of C. neoformans
and infection in patients with AIDS or a unique
strain of C. neoformans that was infecting these
patients (11). Suppression of cellular immunity
appears to be a critical factor in the development
ofcryptococcosisinHIV-infectedpatients,withthe
developmentofdiseaserelatingdirectlytotherisk
for AIDS and to the CD4 lymphocyte count (12,
13).
The appropriate therapy for cryptococcal men-
ingitisinHIV-infectedpatientsisunsettledatthis
time. The combination of amphotericin B plus
flucytosine for 4 to 6 weeks has been considered
standardforpatientswithoutHIVinfection.How-
ever, concern about increased toxicity and de-
creased efficacy (12) has led to a reconsideration
of this regimen in HIV-infected patients.
Several studies have examined the use of oral
fluconazole in lieu of amphotericin B for initial
therapy of cryptococcal meningitis in patients
with HIV infection. Larsen andcolleagues studied
21 patients and found that amphotericin B plus
oral flucytosine resulted in fewer clinical failures
and faster cryptococcal clearance of the cerebro-
spinal fluid than fluconazole alone (14). A large
collaborative trial compared results with a rela-
tively low dose of intravenous amphotericin B to
those with oral fluconazole and found no signifi-
cant difference in the overall mortality rate (15).
However, in this trial, the early mortality rate,
defined as death within the first 2 weeks of ther-
apy, was slightly higher, and time to first negative
CSFculturewassomewhatlongeramongpatients
in the fluconazole group.
The recurrence of cryptococcosis, even after in-
itialtherapy has rendered the CSF culture sterile,
is extremely common in HIV-infected patients
(16); continued antifungal therapy appears to
reducetheriskforrecurrence(12,16).Fluconazole
in daily doses has been shown to be effective in
preventing relapse (16) and is superior to am-
photericin B in weekly doses (17).
Current information suggests that therapy for
cryptococcal meningitis in HIV-infected patients
shouldbeginwithamphotericinB,withorwithout
flucytosine. Suppressive therapy with fluconazole
shouldbegivensubsequentlytopreventarelapse.
When available, the results of a study sponsored
by the Mycoses Study Group and AIDS Clinical
Treatment Group of the National Institute of Al-
lergy and Infectious Diseases, National Institutes
of Health, should clarify these issues.
Histoplasmosis, Coccidioidomycosis, and
Blastomycosis
Unlike candidiasis and cryptococcosis, infec-
tions caused by Histoplasma capsulatum, Coc-
cidioides immitis,a n dBlastomyces dermatitidis
are acquired in specific geographic regions. Infec-
tions due to these fungi were not initially associ-
ated with HIV infectionbecause the HIV epidemic
in the United States began in the large urban
areas of the East and West Coasts, outside the
areas in which these fungi are endemic. As HIV
infection spread to the Midwest, where histoplas-
mosis and blastomycosis are endemic, and to the
Southwest, where coccidioidomycosis occurs,
these fungi became recognized as major opportun-
istic agents.
Histoplasmosis
H.capsulatumvar.capsulatumcausesinfection
worldwide and is the organism most associated
with disease in HIV-infected patients. Afew cases
of histoplasmosis in HIV-infected patients have
been due to H. capsulatum var. duboisii (18),
which is found in tropical Africa. In the Western
Hemisphere, infection is concentrated in the east-
ern United States but is also found in the Carib-
bean as well as in Central and South America. H.
capsulatum var. capsulatum is typically isolated
from soil contaminated with avian or bat excreta,
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out HIV infection have been associated with dis-
ruption of contaminated soil.
Most cases of histoplasmosis in patients with
HIVinfectionhaveoccurredwithintherecognized
areaforendemicH.capsulatuminNorthAmerica,
the Ohio and Mississippi River valleys. However,
within that area, great variability has been seen
in the incidence of disease, with most cases being
reported from a single city, Indianapolis, Indiana
(19, 20). Since 1978, Wheat has recorded several
outbreaks of histoplasmosis in that city, mostly
centered in areas where active construction led to
soil disruption. In the most recent outbreak, pa-
tients with AIDS accounted for more than 50% of
the culture-proven cases of histoplasmosis (21);
these data suggest that many of these cases rep-
resent newinfectionduetorecentexposurerather
than reactivation of latent disease.
Cases ofhistoplasmosis andHIV-infectionhave
also been reported well outside the recognized
histoplasmosis-endemic areas (22, 23). In some
instances, these cases represent reactivation of
infection acquired during residence in or travel to
disease-endemic regions. In other instances, they
appear to represent acute infection after disrup-
tion of microfoci of H. capsulatum that exist out-
side the recognized disease-endemic areas (19).
Patients with progressive disseminated histo-
plasmosis, the most common form of disease
among HIV-infected persons, usually have fever,
malaise, and weight loss over a period of weeks.
Diagnosis is often established by isolating the
fungus from respiratory secretions, blood, or bone
marrow, but detecting Histoplasma capsulatum
var. capsulatum polysaccharide antigen (HPA) in
t h es e r u mo ru r i n ei sa l s oh e l p f u l( 1 9 ) .
Amphotericin B therapy is usually effective for
progressive disseminated histoplasmosis in pa-
tients with HIV infection. Itraconazole may be
usefulforlessseverecases(24).However,relapses
are extremely common when therapy is stopped
(19, 25), and maintenance therapy with intermit-
tent amphotericin B (25) or with itraconazole (26)
is required to prevent this. Fluconazole is less
effective but can be used by those who cannot
tolerate amphotericin B or itraconazole (27).
Urine and serum HPAlevels decline with success-
ful therapy and can be useful in determining a
patient’s response to therapy as well as assessing
a patient for relapse (26-28).
Coccidioidomycosis
Within the disease-endemic area (U.S. South-
west), coccidioidomycosis is one of the most fre-
quent opportunistic infections in persons with
AIDS (29). In a prospective study in Tucson, Ari-
zona, active coccidioidomycosis developed in 25%
of a cohort of HIV-infected patients over a 41-
month period (30). The major risk for developing
disease was immunosuppression, as manifested
by a CD4 lymphocyte count below 250/µl, a diag-
nosis of AIDS, or anergy indicated on control skin
tests. Length of time in the disease-endemic area,
a history of prior coccidioidomycosis, and a posi-
tivecoccidioidalskintestwere not associatedwith
the development of active coccidioidomycosis.
These data suggest that most coccidioidomycosis
casesamongHIV-infectedpersonsinadisease-en-
demic area are recently acquired and not due to
reactivation of latent infection. However, as with
histoplasmosis, in a small number of HIV-infected
patients, previously acquired infection is reacti-
vated, and clinical coccidioidomycosis develops
while the patient is residing outside the disease-
endemic area (29).
Despite recent outbreaks of coccidioidomycosis
in the San Joaquin Valley and in Northridge,
California (31, 32), most cases of coccidioidomy-
cosis among HIV-infected patients have been re-
ported from Arizona, particularly the
metropolitanareasofPhoenixandTucson(30,33).
Whether this represents underreporting of dis-
ease in California or a true increase in incidence
in Arizona is unknown.
MostHIV-infectedpatientswithcoccidioidomy-
cosis seek treatment for pulmonary disease. In
many, chest radiographs show a diffuse, reticu-
lonodular pattern. Approximately 70% of patients
with this pattern die within 1 month despite anti-
fungal therapy (30, 33). In fact, this radiographic
pattern may mimic that seen with Pneumocystis
cariniipneumonia(34).Sitesofdisseminationfre-
quently seen in patients without HIV infection,
suchasskin,softtissue,bone,joint,andmeninges,
appear less common among patients with HIV
infection (30, 33). Serologic tests can be useful in
diagnosing coccidioidomycosis in HIV-infected pa-
tients,althoughtheyaremorelikelytohavenega-
tive results than patients without HIV infection
(35). On the other hand, a positive coccidioidal
complement-fixation serologic test result in an
HIV-infected patient, even in the absence of
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cidioidomycosis (36).
Comparative trials regarding the therapy of
coccidioidomycosis in HIV-infected patients have
not been carried out. For severe disease, such as
for diffuse, reticulonodular pneumonia, am-
photericin B is recommended. However, for less
fulminant infection, fluconazole has been effec-
tive. As with cryptococcosis and histoplasmosis,
life-long maintenance therapy with an oral azole
is recommended, although relapses have occurred
despite this.
Blastomycosis
Blastomycosis is the least common of the three
endemic mycoses in North America among pa-
tients with HIV infection; fewer than 25 cases
have been reported. Only recently has an environ-
mental link been established for infection, when
the organism was isolated from riverbank soil in
association with an outbreak (37).
Pappas and colleagues have publishedthe larg-
est series of cases associated with HIV infection,
consisting of 15 patients from 10 medical centers
(38). Ten of the 15 cases were reported from sites
within the known disease-endemic area, the mid-
western and southeastern United States, and the
other five patients had resided within the disease-
e n d e m i ca r e aa ts o m et i m eb e f o r et h ed i a g n o s i s .
Most patients were clinically immunodeficient at
t h et i m eo fd i a g n o s i sa n dh a de i t h e rc h r o n i cp u l -
monary infection or disease disseminated beyond
the lungs, including meningitis. In all but one
case, the diagnosis was established by culture of
B. dermatitidis, whereas results of serologic tests,
when performed, were uniformly negative. Both
amphotericin B and ketoconazole were used suc-
cessfully as therapy in the series.
Aspergillosis
Although disseminated aspergillosis was origi-
nally listed as an infection at least moderately
predictive of AIDS, it was removed from the list in
1984 because only three cases had been reported
among 1,762 patients (39). However, over the last
5 years, the number of cases of invasive aspergil-
losis among HIV-infected patients has dramati-
cally increased (40-44); more than 75 cases now
have been documented. The largest series, con-
taining 33 patients, was reported by Lortholary
and colleagues from France (43). All patients had
AIDS and a median CD4 lymphocyte count of
27/µl. About half the patients had the traditional
risk factors for invasive aspergillosis(neutropenia
or corticosteroid use) at the time of diagnosis.
Culture of fluid from bronchoalveolar lavage was
positive in all cases in which it was done; A.
fumigatus grew in 29 of 31 patients. In this study,
isolating the fungus from bronchoalveolar lavage
fluid correlated with histologic evidence of inva-
sive aspergillosis in 14 of 15 patients.
In all series, the death rate has been extremely
high despite therapy. Intravenous amphotericin B
has been used most often for treatment, but itra-
conazole has been tried in some instances (40, 43).
In a recent study of the use of itraconazole for the
treatment of invasive aspergillosis in a variety of
patients, therapy was unsuccessful in all 16 pa-
tients with AIDS and aspergillosis (45). In seven
of these, either toxicity to the drug developed or
clinical symptoms worsened while they were re-
ceiving itraconazole; nine died, two directly of
aspergillosis and seven of other causes.
If the incidence of aspergillosis is increasing
among HIV-infected patients, the factors associ-
ated with this increase remain unclear. The iden-
tified risk factors for aspergillosis have no doubt
increased among HIV-infected patients in the last
decade with the use of such drugs as zidovudine
and ganciclovir, which are associated with neu-
tropenia, and corticosteroids for the treatment of
severe Pneumocystis carinii pneumonia and other
conditions. Others have postulated that prior
pneumonia, which may result in diminished
macrophage function (43) and contaminated air,
inhaled during marijuana smoking (40), may also
play a role. Further studies are needed to clarify
this.
Penicilliosis
Piehl and colleagues reported the first case of
infection due to Penicillium marneffei in an AIDS
patient in 1988 when they described a patient in
Chicago with persistent fever, anorexia, and a
papularskinrash.Thepatient’stravelhistorywas
not given. Blood, bone marrow, sputum, and skin
biopsy specimen cultures all grew P. marneffei.
The patient responded to therapy with am-
photericin B, but relapsed once the therapy was
discontinued (46).
Since that report, the number of reported cases
among HIV infected patients has risen rapidly,
particularly in association with the HIV epidemic
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Supparatpinyo and colleagues (47), most patients
were men from the Chiang Mai province of north-
ern Thailand. The most common characteristic in
these patients was a generalized papular rash;
some of the lesions had central ubilication remi-
niscent of molluscum contagiosum. Diagnosis was
usually established by examining Wright-stained
samplesofbonemarrowaspiratesortouchsmears
of skin biopsy specimens.
Treatment with amphotericin B has been suc-
cessful in most patients.Itraconazole andflucona-
zole may also be useful. The mortality rate
appears most related to a delay in diagnosis. Re-
lapse is common once therapy is stopped (48);
therefore, antifungal therapy should be life-long
in the HIV-infected patient with penicilliosis.
In northern Thailand, penicilliosis is now the
third most common opportunistic infection (after
tuberculosis and cryptococcosis) among HIV-in-
fected persons (48). Given that P. marneffei ap-
pears endemic in Southeast Asia, penicilliosis can
be expected to become an even larger problem as
the HIV epidemic continues to expand in this part
of the world.
Prevention of Fungal Infections in HIV-Infected
Patients
With the rise of fungi as opportunistic patho-
gens among patients infected with HIV and with
the success of preventive therapy for other oppor-
tunists, such as P. carinii, primary prevention of
fungal disease in HIV-infected patients should be
pursued. The goal of any such prevention would
be to increase both the length and the quality of
the patient’s life.
Since the availability of the oral azoles, using
antifungal agents to prevent fungal diseases in
HIV-infected patients has become a promising ap-
proach. However, several questions must be con-
sidered before antifungal chemoprophylaxis is
used(49).Istheprevalenceofdiseasehighenough
to make the drug useful in most patients? Is the
efficacy of the drug in preventing disease suffi-
cient?Does the therapyinducethedevelopmentof
drugresistance?Isthecostofthedrugreasonable?
Finally, does the drug have an acceptable toxicity
profile, and does it interact or interfere with the
metabolism of other drugs?
Few answers to these questions are available.
In a recently published prospective, randomized
study comparing fluconazole to topical clotrima-
zole (13), fluconazole was significantly better than
clotrimazole in preventing oropharyngeal and
esophageal candidiasis as well as cryptococcal
meningitis. The benefit of fluconazole was great-
est among patients whose CD4 lymphocyte count
was < 50/µl. However, 10% of the patients had at
least one episode of candidiasis while taking flu-
conazole, which suggests drug resistance. More-
over, the overall and fungal-disease-related death
rates were no different between the two groups.
Given the present data, further studies will be
needed before the issue of primary prevention of
fungal disease through chemoprophylaxis is set-
tled (50).
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